Liquid chromatography-tandem mass spectrometry for quantification of lacosamide, an antiepileptic drug, in rat plasma and its application to pharmacokinetic study

Biomedical Chromatography

Volumn 26, Issue 3, 2012, Pages 371-376

  Kim, Soo Jin ^a   Koo, Tae Sung ^a   Ha, Dong Jin ^a   Baek, Myoungki ^a   Lee, Sang Kil ^b   Shin, Dong Soo ^b   Moon, Hongsik ^a  

^a SK Holdings Co Ltd   (South Korea)

^b Changwon National University   (South Korea)

Author keywords

Antiepileptic drug; Lacosamide; LC MS MS; Pharmacokinetics; Rat plasma

Indexed keywords

ACETONITRILE; BODY FLUIDS; ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; RATS;

ANTIEPILEPTICS DRUGS; ITS APPLICATIONS; LACOSAMIDE; LC-MS-MS; LC.MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; PHARMACOKINETIC STUDIES; PLASMA SAMPLES; RAT PLASMA;

PHARMACOKINETICS;

ACETONITRILE; ANTICONVULSIVE AGENT; FORMIC ACID; HARKOSERIDE; LCD 001; OCTADECYLSILICON DIOXIDE; SILICON DIOXIDE; UNCLASSIFIED DRUG; WATER;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CENTRIFUGATION; COLUMN CHROMATOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; SEPARATION TECHNIQUE; SUPERNATANT; TANDEM MASS SPECTROMETRY;

RATTUS;

EID: 82455161421     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1668     Document Type: Article

References (12)

1. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P and Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308-1317.
2. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U and Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Reviews 2007; 13: 21-42.
3. Buhrman DL, Price PI and Rudewicz PJ. Quantitation of SR 27417 in human plasma using electrospray liquid chromatography-tandem mass spectrometry: a study of ion suppression. Journal of the American Society for Mass Spectrometry 1996; 7: 1099-1105.
4. Cross SA and Curran MP. Lacosamide: in partial-onset seizures. Drugs 2009; 69: 449-459.
5. Errington AC, Coyne L, Stohr T, Selve N and Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006; 50: 1016-1029.
6. Errington AC, Stohr T, Heers C and Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Molecular Pharmacology 2008; 73: 157-169.
7. Greenaway C, Ratnaraj N, Sander JW and Patsalos PN. A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy. Therapeutic Drug Monitoring 2010; 32: 448-452.
8. Greenaway C, Ratnaraj N, Sander JW and Patsalos PN. Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia 2011; 52: 258-263.
9. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D and Sullivan T on behalf of the SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50: 443-453.
10. Koo TS, Kim SJ, Lee J, Ha DJ, Baek M and Moo H Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry. Biomedical Chromatography 2011; DOI: 10.1002/bmc.1625.
11. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019-3030.
12. Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T and Perucca E. Antiepileptic drugs-Best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 239-1276.